A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G Johnson, Elena Peeva, Michael S Vincent, Valerie M Clerin · 2026
Read A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants by Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G Johnson, Elena Peeva, Michael S Vincent, Valerie M Clerin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619095.txt.
Description
Srividya Neelakantan led a 2026 phase 1 trial of PF-07261271, a bispecific antibody that blocks two inflammatory pathways at once for potential use in inflammatory bowel disease. Current drugs usually hit one pathway, so a single agent aimed at both the p40 subunit of interleukin-12/23 and the cytokine TL1A might work better. The randomized, double-blind, placebo-controlled study tested single rising intravenous doses and repeated under-skin doses in healthy adults.
Thirty-five people enrolled, twenty-seven in the single-dose part and eight in the repeated-dose part. The drug was generally safe and well tolerated, with all side effects mild or moderate. Blood levels fell in several phases, with longer persistence at higher doses, and under-skin dosing reached about 48 percent bioavailability. Dose-dependent rises in both targets in blood showed the drug engaged its targets.
Catalog record
| CREATOR | Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G Johnson, Elena Peeva, Michael S Vincent, Valerie M Clerin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |